CDX2: Linking Cell and Patient Fates in Colon Cancer
- PMID: 26849302
- PMCID: PMC5497577
- DOI: 10.1016/j.stem.2016.01.011
CDX2: Linking Cell and Patient Fates in Colon Cancer
Abstract
Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment on
-
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597. N Engl J Med. 2016. PMID: 26789870 Free PMC article.
References
-
-
Dawson, H., Koelzer, V.H., Lukesch, A.C., Mallaev M., Inderbitzin, D., Lugli A., Zlobec, I.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
